ClinicalTrials.gg
Sign In
RecruitingNCT06125444PsoriaticUpdated Dec 8, 2023

Impact of Hyperuricemia on Psoriatic Arthritis

An observational study in Psoriatic Arthritis, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-08.

Sponsored by University Hospital, Strasbourg, France · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as recruiting.
  • Started Aug 2020; still recruiting 6 years 2 months later.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
242
Ages
18 Years and older
Sex
All
01

Study summary

Psoriatic arthritis and gout (linked to hyperuricemia) are two rheumatisms well known to rheumatologists. There are epidemiological and physiopathological arguments in favor of a non-fortuitous link between these two rheumatisms, which to date has not been established. There is currently no recommendation to treat hyperuricaemia without an episode of gout attack. We hypothesize that there is a link between hyperuricemia and severity of rheumatism. This would ultimately modify the therapeutic management of hyperuricemic patients followed for psoriatic arthritis.

02

Conditions studied

  • Psoriatic Arthritis

Keywords

  • Psoriatic Arthritis
  • Hyperuricemia
  • Rheumatisms
03

In context

Arthritis, Psoriatic

600 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

This study's planned enrollment of 242 is below the median of 300 across 243 observational studies indexed under Arthritis, Psoriatic.

Browse Arthritis, Psoriatic studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.

Browse University Hospital, Strasbourg, France studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Major subject (≥18 years old), with a history of psoriatic arthritis objectified according to the CIM 10-1 coding for patients followed in hospitalization at the HUS and HCC and subject presenting psoriatic arthritis objectified during a consultation by an HCC rheumatologist

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Major subject (≥18 years old)
  • Subject with a history of psoriatic arthritis objectified according to the CIM 10-1 coding for patients followed in hospitalization at the HUS and HCC
  • Subject presenting psoriatic arthritis objectified during a consultation by an HCC rheumatologist
  • Among these two populations, all subjects for whom at least one serum uric acid assay was available in the medical file
  • Subject having not expressed, after being informed, opposition to the reuse of their data for research purposes

Exclusion criteria

Exclusion criteria:

  • Subject who expressed their opposition to participating in the study
  • Subject who met the inclusion criteria but whose analysis of the medical file (anamnestic, clinical, biological and radiological data) led to a diagnostic reversal and therefore did not present with psoriatic arthritis
  • Subject under guardianship or curatorship
  • Subject under safeguard of justice
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
242 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Retrospectively determine the impact of hyperuricemia on the response to psoriatic arthritis treatments: inventory of the latest treatments in progress and the response to treatment according to the treating rheumatologist

    Time frame: Files analysed retrospectively from January 01, 2009 to December 31, 2019 will be examined

07

Study locations

1 of 1 sites recruiting
  • Service de Rhumatologie - CHU de Strasbourg - France
    Strasbourg, 67091, France
    Recruiting
    • Renaud FELTEN, MD, PhD · Contactrenaud.felten@chru-strasbourg.fr · 33 3 88 12 79 64
    • Renaud FELTEN, MD · Principal investigator
    • Laura WIDAWSKI, MD · Sub investigator
    • Laurent MESSER, MD · Principal investigator
    • Thibaut FABACHER, Statistician · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2020 (actual). Primary completion is estimated for Dec 2023, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2022
First posted
Nov 9, 2023
StartActual
Aug 24, 2020
Primary completionEst.
Dec 2023
CompletionEst.
Dec 31, 2023
Last update
Dec 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06125444
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Nov 9, 2023
Start date
Aug 24, 2020
Primary completion
Dec 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Dec 8, 2023

Study contacts

Renaud FELTEN, MD
Contact
renaud.felten@chru-strasbourg.fr
33 3 88 12 79 64

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Arthritis, Psoriatic →

Other studies from this sponsor

University Hospital, Strasbourg, France →

Start the discussion